Article
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jun 2025
Zampini Matteo, Riva Elena, Lanino Luca, Sauta Elisabetta, Antunes Dos Reis Rita, Ejarque Rosa Maria Andres, Maggioni Giulia, Termanini Alberto, Merlotti Alessandra, Campagna Alessia, Dall'Olio Lorenzo, Kulasekararaj Austin, Calvi Michela, Di Vito Clara, Bonometti Arturo, Rahal Daoud, Croci Giorgio, Boveri Emanuela, Gianelli Umberto, Ponzoni Maurilio, Caselli Rossella, Albertazzi Serena, Todisco Gabriele, Ubezio Marta, Crisafulli Laura, Frigo Alessandro, Lugli Enrico, Mosca Ettore, Acha Pamela, Ghisletti Serena, Nicassio Francesco, Santoro Armando, Diez-Campelo Maria, Solé Francesc, Ades Lionel, Platzbecker Uwe, Santini Valeria, Fenaux Pierre, Haferlach Torsten, Sallman David, Garcia-Manero Guillermo, Mavilio Domenico, Remondini Daniel, Castellani Gastone, D'Amico Saverio, Zeidan Amer M, Komrokji Rami, Kordasti Shahram, Ficara Francesca, Della Porta Matteo Giovanni
Abstract excerpt
PURPOSE: Tumor Protein 53 (p53) expressed from gene TP53 is a seminal tumor suppressor. We aimed to characterize mutational and nonmutational mechanisms of p53 dysfunction in myelodysplastic syndromes (MDS) and to investigate their clinical effect. PATIENTS AND METHODS: We analyzed a cohort of 6,204 patients with MDS and subsets of patients with available information on RNA sequencing of tumor cells (n = 109),...
Topics
Join the communities discussing this publication.